Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vicarious Surgical ( (RBOT) ) has shared an announcement.
On March 3, 2026, Vicarious Surgical received notice that the New York Stock Exchange would immediately suspend trading and begin delisting its common stock after the company fell below the exchange’s $15 million average global market capitalization requirement over 30 trading days. Trading in the shares, which had been listed under the symbol RBOT, was halted after the March 3 market close as the company began evaluating whether to appeal the NYSE determination.
Vicarious Surgical has secured approval to have its stock quoted on the OTCID tier of OTC Markets, with trading expected to begin on March 4, 2026 under the same ticker, offering investors a more limited and potentially less liquid venue. The move off the NYSE is expected to reduce liquidity and could pressure the share price, while also constraining the company’s access to public equity financing and its ability to use stock-based incentives, potentially affecting existing shareholders, capital-raising plans and employee compensation.
On March 4, 2026, the company issued a press release formally announcing the NYSE delisting notice, the trading suspension and the planned transition of its shares to the OTC market. The announced changes underscore the financial market pressures facing the surgical robotics group as it pursues development and eventual commercialization of its Vicarious Surgical System and related technologies.
The most recent analyst rating on (RBOT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vicarious Surgical stock, see the RBOT Stock Forecast page.
Spark’s Take on RBOT Stock
According to Spark, TipRanks’ AI Analyst, RBOT is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, large ongoing losses, heavy cash burn, and sharply reduced equity). Technicals also remain unfavorable with a clear longer-term downtrend and negative MACD. Offsetting factors include cost-cutting progress and improved cash-burn guidance plus financing actions, but these are not yet enough to outweigh the current funding and execution risk.
To see Spark’s full report on RBOT stock, click here.
More about Vicarious Surgical
Vicarious Surgical Inc. is a next-generation surgical robotics company developing proprietary human‑like robots designed to virtually transport surgeons inside the patient for minimally invasive procedures. Founded in 2014 and headquartered in Waltham, Massachusetts, it targets improving surgical efficiency, patient outcomes and healthcare costs in the medical device and robotic surgery markets.
Average Trading Volume: 122,881
Technical Sentiment Signal: Sell
Current Market Cap: $13.67M
For an in-depth examination of RBOT stock, go to TipRanks’ Overview page.